Gut Microbiota-Derived TMAO : A Causal Factor Promoting Atherosclerotic Cardiovascular Disease?
Canyelles, Marina (Institut d'Investigació Biomèdica Sant Pau)
Borràs, Carla (Institut de Recerca Sant Pau)
Rotllan, Noemi (Institut de Recerca Sant Pau)
Tondo, Mireia (Institut de Recerca Sant Pau)
Escolà-Gil, Joan Carles (Institut de Recerca Sant Pau)
Blanco Vaca, Francisco (Institut de Recerca Sant Pau)
Universitat Autònoma de Barcelona

Fecha:	2023
Resumen:	Trimethylamine-N-oxide (TMAO) is the main diet-induced metabolite produced by the gut microbiota, and it is mainly eliminated through renal excretion. TMAO has been correlated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) and related complications, such as cardiovascular mortality or major adverse cardiovascular events (MACE). Meta-analyses have postulated that high circulating TMAO levels are associated with an increased risk of cardiovascular events and all-cause mortality, but the link between TMAO and CVD remains not fully consistent. The results of prospective studies vary depending on the target population and the outcome studied, and the adjustment for renal function tends to decrease or reverse the significant association between TMAO and the outcome studied, strongly suggesting that the association is substantially mediated by renal function. Importantly, one Mendelian randomization study did not find a significant association between genetically predicted higher TMAO levels and cardiometabolic disease, but another found a positive causal relationship between TMAO levels and systolic blood pressure, which-at least in part-could explain the link with renal function. The mechanisms by which TMAO can increase this risk are not clearly elucidated, but current evidence indicates that TMAO induces cholesterol metabolism alterations, inflammation, endothelial dysfunction, and platelet activation. Overall, there is no fully conclusive evidence that TMAO is a causal factor of ASCVD, and, especially, whether TMAO induces or just is a marker of hypertension and renal dysfunction requires further study.
Ayudas:	Instituto de Salud Carlos III PI18-00164 Instituto de Salud Carlos III PI19-00136 Ministerio de Ciencia, Innovación y Universidades PID2019-104367RB-100 Instituto de Salud Carlos III Rio Hortega contract CM20/00033
Nota:	Altres ajuts: Red de Investigación en "Enfermedades Metabólicas y Cáncer", RED2018-102799-T ; FPU (Formación de Profesorado Universitario), FPU20/07440
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article de revisió ; recerca ; Versió publicada
Materia:	Atherosclerosis ; TMAO ; Mortality ; CVD ; Renal function ; Prospective
Publicado en:	International journal of molecular sciences, Vol. 24 (january 2023) , ISSN 1422-0067

DOI: 10.3390/ijms24031940
PMID: 36768264

17 p, 942.7 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados